Rybrevant® (amivantamab-vmjw) – New indication, accelerated approval converted to full approval
March 1, 2024 - Johnson & Johnson announced the FDA approval of Rybrevant (amivantamab-vmjw), in combination with carboplatin and pemetrexed, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.
Top